Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

- Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP^® companion diagnostic

- Secured new service contract with EU biotech for Allarity Medical Laboratory

Read more at globenewswire.com